Sign in Create account

Senores Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SENORES BSE: 544319
₹1385.80
▼ -17.90 (-1.28%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
57/100
Moderate
Valuation
—/100
Expensive
Momentum
32/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹6,382 Cr
PE (TTM)
254.7
Industry median 36.1 (152 companies)
Price to Book
6.6
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
16.39%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
16.2
Relative return vs Sector, qtr %
5.5
Free Cash Flow
₹-178 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-62.71%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
-61.85%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
36.18%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.92
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.34
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
4.39
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
3.82%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
13.38%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
25.56%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.58%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.61%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
12.60%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.34)
  • No Return on equity is 15% or more (12.6%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (2.8% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.3%
Low 1370.0000 · High 1413.0000
1W return
0.2%
Low 1336.3000 · High 1435.0000
1M return
-3.3%
Low 1336.3000 · High 1532.0000
52W return
93.7%
Low 700.7500 · High 1599.0000
Lifetime High ₹1550.9000 (Aug. 19, 2026)
Lifetime Low ₹444.3000 (Jan. 13, 2025)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
1380.0
10D
1387.1
20D
1406.0
50D
1397.7
100D
1304.3
200D
1067.2

Delivery and volume

Day avg. delivery
51.4%
Week avg. delivery
42.7%
Month avg. delivery
48.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1389.60
Pivot
First resistance1409.20
Second resistance1432.60
Third resistance1452.20
First support1366.20
Second support1346.60
Third support1323.20
Day RSI45.4
Day MFI50.6
Day MACD-19.98
Day MACD signal-15.05

Beta

1M0.75
3M0.04
1Y0.89
3Y1.15

Price change analysis

↓ -3.3%
Over 1 Month
LowHigh
1336.301532.00
↑ 5.5%
Over 3 Months
LowHigh
1279.701599.00
↑ 79.1%
Over 6 Months
LowHigh
741.901599.00
↑ 93.7%
Over 1 Year
LowHigh
700.751599.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 254.7 (own history: 130.7–255.1)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹27 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.2200

Ranks #56 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter45.82%
  • Mutual funds6.56%
  • FII/FPI6.62%
  • Other DII3.21%
  • Public37.79%

Largest holders

NameCategoryShares %Shares
Swapnil Jatin ShahPromoter7.7200%3553531
Ashokbhai Vijaysinh BarotPromoter7.4800%3444869
Remus Pharmaceuticals LimitedPromoter7.0800%3261744
Renosen Pharmaceuticals Private LimitedPromoter5.9000%2718719
Anar Swapnil ShahPromoter4.9800%2294500

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 45.82% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 3.64% to 6.62% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 5.07% to 6.56% in Jun 2026 qtr

4 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 86 insider trades, 19 SAST, 4 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
1 Apr 2026 Swapnil Jatin Shah Promoter Buy 0 ₹0
1 Apr 2026 Ashokbhai Vijaysinh Barot Promoter Buy 0 ₹0
1 Apr 2026 Viraj Ashokkumar Barot Promoter group Buy 0 ₹0
1 Apr 2026 Renosen Pharmaceuticals Private Limited Promoter group Buy 0 ₹0
1 Apr 2026 Sangeeta Mukur Barot Promoter group Buy 0 ₹0
2 Mar 2026 Dhruvalben Vishal Shah Other Buy 0 ₹0
17 Feb 2026 Espee Therapeutics LLP Promoter group Pledge 0 ₹31.34 Cr
17 Feb 2026 Renosen Pharmaceuticals Private Limited Promoter group Pledge Revoke 0 ₹31.34 Cr
1 Jan 2026 Renosen Pharmaceuticals Private Limited Promoter group Buy 0 ₹0
18 Dec 2025 Renosen Pharmaceuticals Private Limited Promoter group Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 21 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
24 Dec 2025 ASTORNE CAPITAL VCC ARVEN Bulk Sell 500,000 792.1200 NSE
24 Dec 2025 YASHKUMAR SHANTILAL SANGHVI Bulk Sell 276,270 792.0000 BSE
24 Dec 2025 RAVI PAWANKUMAR SANGHVI Bulk Sell 292,500 792.1900 BSE
29 Jul 2025 HRTI PRIVATE LIMITED Bulk Buy 269,264 686.6600 NSE
29 Jul 2025 HRTI PRIVATE LIMITED Bulk Sell 237,321 688.8700 NSE
29 Jul 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 316,091 689.9800 NSE
29 Jul 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 316,091 689.3300 NSE
6 Feb 2025 QE SECURITIES LLP Bulk Sell 280,836 612.4900 NSE
6 Feb 2025 QE SECURITIES LLP Bulk Buy 246,061 609.0100 NSE
6 Feb 2025 HRTI PRIVATE LIMITED Bulk Buy 297,095 617.6500 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
27 Jul 2026 Financial Results/Other business matters Yes
14 May 2026 Financial Results/Other business matters Yes
20 Jan 2026 Financial Results/Other business matters Yes
7 Jan 2026 Fund Raising/Other business matters —
6 Nov 2025 Financial Results/Other business matters Yes

Corporate Announcements

All 209 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 AGM/EGM Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
28 Sep 2026 Shareholders meeting Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting
25 Sep 2026 Shareholders meeting Senores Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026
25 Sep 2026 AGM/EGM Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Outcome of AGM
24 Sep 2026 Trading Window Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
21 Sep 2026 General Updates Senores Pharmaceuticals Limited has informed the Exchange about General Updates
21 Sep 2026 Company Update Senores Pharmaceuticals Ltd - 544319 - Clarification sought from Senores Pharmaceuticals Ltd
21 Sep 2026 Company Update Senores Pharmaceuticals Ltd - 544319 - Clarification On Movement In Volume
11 Sep 2026 Company Update Senores Pharmaceuticals Ltd - 544319 - Successful Completion Of USFDA Inspection
11 Sep 2026 General Updates Senores Pharmaceuticals Limited has informed the Exchange about Successful Completion of USFDA Inspection

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Healthy liquidity (Current Ratio 1.92)
  • Strong revenue growth YoY (36.2%)

Weaknesses

  • Thin net profit margin (3.8%)
  • Declining profit YoY (-61.9%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (254.7) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Senores Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.